(C) Reuters. FILE PHOTO: U.S. President Joe Biden delivers remarks on the Build Back Better Act and its impact on the cost of prescription drugs during a speech in the East Room at the White House in Washington, U.S., December 6, 2021. REUTERS/Leah Millis
By Jeff Mason and Trevor Hunnicutt
IRVINE, Calif. (Reuters) -U.S. President Joe Biden criticized Republicans and drug companies during a stop at a California community college, as he campaigned for fellow Democrats in November’s midterm elections as his party tries to retain thin margins in Congress.
The trip includes stops in California on Friday and Oregon on Saturday as Biden positions his party as a champion of consumers and lower healthcare costs at a time that inflation ranks among voters’ top concerns. The midterm elections are on Nov. 8.
“We took on Big Pharma and we beat them, finally,” Biden said, referring to the recently passed Inflation Reduction Act’s provisions allowing Medicare to negotiate lower drug prices; caps the costs senior citizens will pay for prescriptions; and brings insulin prescriptions down to $35 for Medicare beneficiaries.
Biden promised to cap the insulin price at $35 for all Americans if Democrats keep the House and Senate. Most forecasts show Democrats with a slight advantage in the Senate and Republicans with a larger advantage in the House.
Biden alleged that Republicans will repeal the prescription drug price caps and take away Medicare’s ability to negotiate drug prices if they take control.
Biden was introduced by Representative Katie Porter, who has grilled bank and drug company executives on their profits in widely viewed Congressional hearings.
“Here’s the stone cold truth. Corporate greed worsens health outcomes, rips off taxpayers and threatens our capitalist economy,” Porter said, alleging the pharmaceutical industry was crushing competition and price transparency.
Biden signed an order Friday requiring the U.S. Department of Health & Human Services (HHS) to outline within 90 days how it will use new models of care and payment to cut drug costs.
Data on Thursday showed U.S. consumer prices jumped 8.2% in the 12 months through September, after peaking above 9% in the summer and growing at their fastest pace since 1981. Healthcare costs were partly to blame in the most recent month, along with food and rent.
“Americans are squeezed by the cost of living – that’s been true for years and is a key reason the president ran,” the White House said in a fact sheet blaming pharmaceutical companies for raising prices. “Health care costs in particular are driving inflation.”
HHS was given the power to promote new approaches to lowering costs and widening care through an Innovation Center, created by a 2010 healthcare reform law known as Obamacare and housed at the Centers for Medicare and Medicaid Services.
In August, Biden signed the $430 billion Inflation Reduction Act.
Some 65 million Americans are enrolled in Medicare programs, which have repeatedly come under fire for its cost to taxpayers.
(C) 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.